Sugawara, Masahiro
Goto, Yoshio
Yamazaki, Tsutomu
Teramoto, Tamio
Oikawa, Shinichi
Shimada, Kazuyuki
Uchiyama, Shinichiro
Ando, Katsuyuki
Ishizuka, Naoki
Murata, Mitsuru
Yokoyama, Kenji
Uemura, Yukari
Ikeda, Yasuo
Teramoto, Tamio
Shimada, Kazuyuki
Uchiyama, Shinichiro
Sugawara, Masahiro
Goto, Yoshio
Yamada, Nobuhiro
Yamazaki, Tsutomu
Oikawa, Shinichi
Fujita, Toshiro
Hosoda, Saichi
Origasa, Hideki
Shinohara, Yukito
Yamamoto, Akira
Uchiyama, Shinichiro
Matsumoto, Masayasu
Minematsu, Kazuo
Shimada, Kazuyuki
Daida, Hiroyuki
Ogawa, Hisao
Yokoyama, Kenji
Murata, Mitsuru
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)—A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events
https://doi.org/10.1016/j.ahj.2009.11.030
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70)
https://doi.org/10.1007/s40256-018-0313-0
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (200400519A)
Waksman Foundation of Japan
Article History
First Online: 18 December 2018
Compliance with Ethical Standards
:
: TY reports receiving personal fees from AstraZeneca, Dainippon Sumitomo, Shionogi, and Takeda. TT reports receiving grant support from Daiichi Sankyo, Eli Lilly, Kowa, Shionogi, and Takeda; speaker fees from Amgen Astellas BioPharma, Astellas, Bayer, Daiichi Sankyo, Kissei, Kowa, Pfizer, Sanofi, and Takeda; and department endowments from Aska, Astellas, Bayer, Kissei, Kowa, and MSD. SO reports receiving personal fees from Astellas, Bayer, Daiichi Sankyo, Kyowa Hakko Kirin, Mochida, MSD, and Takeda. SU reports receiving speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Dainihon Sumitomo, Otsuka, Shionogi, Takeda, and Tanabe Mitsubishi. KA reports receiving speaker fees from Bayer, Daiichi Sankyo, Mochida, MSD, and Torii Pharmaceutical. NI reports being a former employee of Sanofi-Aventis. MM reports receiving grant support from Bayer, Daiichi Sanko, Pfizer, Sanofi-Aventis, and Taisho-Toyama, and personal fees from Dainihon-Sumitomo, Otsuka, and Taisho-Toyama. KY reports grants from Nippon Shinyaku, Bristol-Myers Squibb, Chugai, Takeda, Pfizer, Kyowa Hakko Kirin, and Eisai, and personal fees from Nippon Shinyaku, Celgene Japan, Bayer, Bristol-Myers Squibb, Novartis, Takeda, Pfizer, Kyowa Hakko Kirin, and Otsuka. YU reports receiving grants from the JPPP study secretariat. YI reports receiving fees for medical advice from AstraZeneca, Bayer, Daiichi Sankyo, GlaxoSmithKline, and Sanofi-Aventis. MS, YG, and KS declare no conflicts of interest.
: The JPPP was sponsored by the Japanese Ministry of Health, Labour, and Welfare (Grant Number 200400519A) and the Waksman Foundation of Japan. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Enteric-coated 100-mg aspirin tablets were provided free of charge by Bayer Yakuhin, Japan.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.